NRG/HER Restoration of the Lung Epithelium After Injury

NRG/HER 损伤后肺上皮的恢复

基本信息

  • 批准号:
    7459815
  • 负责人:
  • 金额:
    $ 36.62万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-09-01 至 2010-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Acute lung injury with its associated damage to the pulmonary epithelium and the resultant fibrosis affects approximately 20/100,000 /year in the US. Pulmonary epithelial cells, growth factors and their cognate receptors play an active role in this recovery. However, which growth factors and receptors participate and what processes they direct remains unclear. My laboratory has identified a membrane bound receptor tyrosine kinase family in the lung, the human epidermal growth factor-like receptor family (HER2, 3 and 4), whose expression is localized to the pulmonary epithelium. Our studies of the HER system and its ligand, Neuregulin-1 (NRG-1), suggest they play an important role in the recovery of pulmonary epithelial cells from injury. This knowledge has led us to hypothesize that: Activation of the HER2/HER3 receptor in pulmonary epithelial cells during or after lung injury directs a fibrotic response via the elaboration of pro-fibrotic cytokine cascades and promotes epithelial cell repair. The goal of this proposal is to test this hypothesis in vivo using transgenic mice with lung specific defects in the NRG-1/HER2/HER3 axis and define mechanisms of receptor activation and downstream signaling in vitro. In this application we propose to: 1) Define the HER2/HER3 receptor complex's role in the regulation of fibrotic cytokine cascades using unique transgenic mouse strains with lung specific expression of a dominant negative HERS receptor, 2) Define mechanisms of HER2/HER3 receptor activation during injury that results in fibrotic cytokine production, and 3) Use a dominant negative STAT3 molecule to understand the HER2/HER3 induced activation of STAT3, and its role in repair of the epithelium. Bleomycin and mechanical injury models will be used in vivo and in vitro to initiate lung injury and determine the effect(s) of HER2/HER3 receptor activation and inactivation on the epithelium's ability to direct fibrosis, inflammation, proliferation, and apoptosis. The identification of growth factors, receptors, and induced signals important in the pulmonary repair process will lay the groundwork for identification of new therapeutic strategies for patients with fibrotic or otherwise damaged lungs.
描述(由申请方提供):在美国,急性肺损伤及其相关的肺上皮损伤和由此产生的纤维化的影响率约为20/100,000/年。肺上皮细胞、生长因子及其同源受体在这种恢复中起着积极的作用。 然而,哪些生长因子和受体参与以及它们指导的过程仍然不清楚。 我的实验室已经鉴定了肺中的膜结合受体酪氨酸激酶家族,即人表皮生长因子样受体家族(HER 2、3和4),其表达定位于肺上皮。 我们对HER系统及其配体Neuregulin-1(NRG-1)的研究表明,它们在肺上皮细胞损伤的恢复中起重要作用。这一知识使我们假设:在肺损伤期间或之后,肺上皮细胞中HER 2/HER 3受体的激活通过促纤维化细胞因子级联的产生指导纤维化反应并促进上皮细胞修复。 本提案的目的是使用NRG-1/HER 2/HER 3轴中具有肺特异性缺陷的转基因小鼠在体内测试该假设,并定义体外受体激活和下游信号传导的机制。 在本申请中,我们提出:1)使用具有显性阴性HERS受体的肺特异性表达的独特转基因小鼠品系,确定HER 2/HER 3受体复合物在纤维化细胞因子级联调节中的作用,2)确定导致纤维化细胞因子产生的损伤期间HER 2/HER 3受体活化的机制,和3)使用显性负性STAT 3分子来理解HER 2/HER 3诱导的STAT 3活化及其在上皮修复中的作用。 博来霉素和机械损伤模型将在体内和体外用于引发肺损伤并确定HER 2/HER 3受体活化和失活对上皮细胞指导纤维化、炎症、增殖和凋亡的能力的影响。 对肺修复过程中重要的生长因子、受体和诱导信号的鉴定将为鉴定肺纤维化或其他损伤患者的新治疗策略奠定基础。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Interleukin-6 is required for Neuregulin-1 induced HER2 signaling in lung epithelium.
Neuregulin-1 诱导肺上皮中的 HER2 信号转导需要 Interleukin-6。
Role of Smad2/3 and p38 MAP kinase in TGF-β1-induced epithelial-mesenchymal transition of pulmonary epithelial cells.
  • DOI:
    10.1002/jcp.22448
  • 发表时间:
    2011-05
  • 期刊:
  • 影响因子:
    5.6
  • 作者:
    Kolosova, Irina;Nethery, David;Kern, Jeffrey A.
  • 通讯作者:
    Kern, Jeffrey A.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JEFFREY A KERN其他文献

JEFFREY A KERN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JEFFREY A KERN', 18)}}的其他基金

Identification of pathways to mitigate Immune-Related Adverse Events with Cancer Immunotherapy
确定通过癌症免疫治疗减轻免疫相关不良事件的途径
  • 批准号:
    10395923
  • 财政年份:
    2020
  • 资助金额:
    $ 36.62万
  • 项目类别:
Identification of pathways to mitigate Immune-Related Adverse Events with Cancer Immunotherapy
确定通过癌症免疫治疗减轻免疫相关不良事件的途径
  • 批准号:
    10593951
  • 财政年份:
    2020
  • 资助金额:
    $ 36.62万
  • 项目类别:
Identification of pathways to mitigate Immune-Related Adverse Events with Cancer Immunotherapy
确定通过癌症免疫治疗减轻免疫相关不良事件的途径
  • 批准号:
    9920595
  • 财政年份:
    2020
  • 资助金额:
    $ 36.62万
  • 项目类别:
NRG/HER Restoration of the Lung Epithelium After Injury
NRG/HER 损伤后肺上皮的恢复
  • 批准号:
    6979291
  • 财政年份:
    2005
  • 资助金额:
    $ 36.62万
  • 项目类别:
NRG/HER Restoration of the Lung Epithelium After Injury
NRG/HER 损伤后肺上皮的恢复
  • 批准号:
    7255627
  • 财政年份:
    2005
  • 资助金额:
    $ 36.62万
  • 项目类别:
NRG/HER Restoration of the Lung Epithelium After Injury
NRG/HER 损伤后肺上皮的恢复
  • 批准号:
    7116266
  • 财政年份:
    2005
  • 资助金额:
    $ 36.62万
  • 项目类别:
HER RECEPTOR FAMILY, HEREGULIN AND LUNG DEVELOPMENT
她的受体家族、调节蛋白和肺部发育
  • 批准号:
    6476863
  • 财政年份:
    2000
  • 资助金额:
    $ 36.62万
  • 项目类别:
HER RECEPTOR FAMILY, HEREGULIN AND LUNG DEVELOPMENT
她的受体家族、调节蛋白和肺部发育
  • 批准号:
    6330165
  • 财政年份:
    2000
  • 资助金额:
    $ 36.62万
  • 项目类别:
HER RECEPTOR FAMILY, HEREGULIN AND LUNG DEVELOPMENT
她的受体家族、调节蛋白和肺部发育
  • 批准号:
    2758559
  • 财政年份:
    1998
  • 资助金额:
    $ 36.62万
  • 项目类别:
HER RECEPTOR FAMILY, HEREGULIN AND LUNG DEVELOPMENT
她的受体家族、调节蛋白和肺部发育
  • 批准号:
    6125878
  • 财政年份:
    1998
  • 资助金额:
    $ 36.62万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 36.62万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.62万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 36.62万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.62万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 36.62万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.62万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 36.62万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 36.62万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 36.62万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.62万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了